The graft-versus-leukemia (GVL) effect of this successful immunotherapy is due to recognition by donor T-cells of minor histocompatibility antigens (MiHA) expressed on malignant hematopoietic recipient cells [3]–[6]. Here, XIAP is linked to leukemia.